Amneal Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 6c
August 9, 2021 6:03 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $535 million versus the consensus estimate of $523.25 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2021 EPS of $0.70-$0.85, versus the consensus of $0.82. Amneal... More
